BURP9 Antibody

What is BP9 and what is its structural composition?

BP9 (Bursal nonapeptide) is a biologically active oligopeptide isolated from the bursa of Fabricius, a central humoral immune organ unique to birds. Structurally, BP9 consists of nine specific amino acids: Leucine-Methionine-Threonine-Phenylalanine-Arginine-Asparagine-Glutamic acid-Glycine-Threonine (Leu-Met-Thr-Phe-Arg-Asn-Glu-Gly-Thr). This sequence was identified through rigorous isolation techniques including RP-HPLC, MODIL-TOP-MS, and MS/MS analysis .

Methodologically, researchers studying BP9 should utilize appropriate peptide synthesis approaches to ensure sequence fidelity when working with synthetic versions. Circular dichroism spectroscopy can be employed to verify the secondary structure, which may influence its biological activity.

What are the primary immunological functions of BP9?

BP9 demonstrates significant immunomodulatory functions, particularly in enhancing antibody responses and influencing B cell development. Research has shown that BP9:

• Enhances antibody production when co-administered with vaccines (demonstrated in both avian and murine models)

• Stimulates surface IgM (sIgM) expression in avian B cells

• Modulates lymphocyte viability

• Regulates multiple immune-related biological processes including cytokine production and T cell activation

• Induces autophagy in immature B cells

These functions were experimentally validated through in vivo immunization protocols and in vitro cell culture systems using DT40 cells (avian B cell line) and WEHI-231 cells (murine immature B cell line) .

How does BP9 affect vaccine responses?

BP9 significantly enhances vaccine-induced antibody responses when used as an adjuvant. In experimental studies, mice injected with 0.01 and 0.05 mg/mL BP9 plus Japanese Encephalitis Virus (JEV) vaccine generated significantly higher antibody levels compared to control groups receiving the vaccine alone . Similarly, when co-administered with Avian Influenza Virus (AIV) inactivated vaccine in 21-day-old chickens, BP9 promoted elevated AIV-specific Hemagglutination Inhibition (HI) antibody titers and enhanced lymphocyte viability .

To replicate these findings, researchers should carefully consider dosage optimization, timing of administration, and appropriate controls when designing experiments to evaluate BP9's adjuvant properties.

What molecular pathways does BP9 modulate in immature B cells?

BP9 influences multiple signaling pathways and biological processes in immature B cells. Microarray analysis of BP9-treated WEHI-231 cells revealed differential regulation of genes involved in:

• Cytokine production regulation

• T cell activation

• Multiple immune-related processes

Network analysis identified four significantly enriched pathways in BP9-treated immature B cells . Additionally, in DT40 cells treated with 0.2 μg/mL BP9, gene expression profiling demonstrated 598 upregulated genes and 395 downregulated genes .

For robust pathway analysis, researchers should employ both transcriptomic (RNA-seq or microarray) and proteomic approaches, followed by validation of key pathway components through techniques such as Western blotting, qPCR, or phosphorylation-specific assays.

How does BP9 influence autophagy in B cells and what are the implications for immune regulation?

BP9 has been demonstrated to induce autophagy formation in immature B cells, a process with significant implications for B cell development and immune regulation. Mechanistically, BP9 stimulates AMPK-ULK1 phosphorylation, a critical step in autophagy initiation . This finding suggests BP9 may influence B cell development and function through regulation of autophagic processes.

To investigate this phenomenon, researchers should:

• Employ autophagy markers (LC3-II, p62/SQSTM1) via Western blotting and immunofluorescence

• Utilize autophagy inhibitors (like 3-methyladenine or chloroquine) as experimental controls

• Monitor AMPK-ULK1 pathway activation through phospho-specific antibodies

• Assess functional outcomes of autophagy modulation on B cell development, survival, and antibody production

This area represents a promising direction for understanding how BP9 influences immune cell development through fundamental cellular processes.

What are the differences between BP9 effects on avian versus mammalian B cells?

While BP9 was originally isolated from avian bursa, research indicates it has immunomodulatory effects in both avian and mammalian systems. In avian models (using DT40 cells), BP9 promotes sIgM expression and modulates multiple immune-related pathways . In mammalian models, BP9 enhances vaccine-induced antibody responses in mice and affects signaling pathways in murine WEHI-231 cells .

These cross-species effects suggest evolutionary conservation of BP9's target molecules, though researchers should note potential differences in:

• Receptor binding affinities

• Downstream signaling pathway activation

• Functional outcomes on B cell development and antibody production

Comparative studies using equivalent doses and experimental conditions across species are essential to fully characterize these differences. Techniques such as surface plasmon resonance (SPR) could help identify potential receptors in different species.

What are the optimal experimental methods for studying BP9's effects on antibody production?

To rigorously investigate BP9's effects on antibody production, researchers should employ a multi-faceted approach:

In vivo protocols:

• Administer BP9 alongside test antigens or vaccines at optimized doses (0.01-0.05 mg/mL has been effective in mice; dosage may require adjustment for other species)

• Include proper controls: antigen-only, adjuvant-only, and naive groups

• Collect serum at multiple timepoints post-immunization

• Measure antibody titers using ELISA, HI assays, or virus neutralization tests as appropriate

• Assess antibody isotype distribution to evaluate qualitative aspects of the response

In vitro approaches:

• Culture primary B cells or appropriate B cell lines (e.g., DT40 for avian studies, WEHI-231 for mammalian studies)

• Treat with BP9 at concentrations ranging from 0.02 to 2 μg/mL

• Measure sIgM expression by flow cytometry and qPCR

• Assess B cell activation markers, proliferation, and viability

• Analyze antibody secretion in culture supernatants by ELISA

These methodological approaches provide complementary insights into how BP9 affects both the quantity and quality of antibody responses .

How can researchers effectively analyze BP9-induced changes in gene expression?

To comprehensively analyze BP9-induced changes in gene expression, researchers should implement the following methodological workflow:

• Experimental design:

  • Treat cells with BP9 at multiple concentrations (0.02-2 μg/mL) and timepoints (4h and 20h have been informative)

  • Include appropriate controls and biological replicates

• Gene expression profiling:

  • Use RNA-seq or microarray analysis for genome-wide expression profiling

  • Validate key findings with qPCR using properly designed primers and reference genes

• Bioinformatic analysis:

  • Identify differentially expressed genes using appropriate statistical methods

  • Perform pathway enrichment analysis using databases such as KEGG, GO, or Reactome

  • Conduct network analysis to identify functional gene clusters and hub genes

• Validation studies:

  • Confirm protein-level changes for selected genes using Western blotting or proteomics

  • Perform functional studies to verify the biological significance of identified pathways

Previous studies identified 598 upregulated and 395 downregulated genes in BP9-treated DT40 cells, with enrichment in six pathways and eight signaling systems . This provides a valuable reference point for new investigations.

What techniques should be used to investigate BP9's role in autophagy regulation?

To investigate BP9's role in autophagy regulation, researchers should employ these methodological approaches:

• Autophagy detection:

  • Monitor LC3-I to LC3-II conversion via Western blotting

  • Visualize autophagosome formation using fluorescence microscopy with GFP-LC3 constructs

  • Assess autophagic flux using lysosomal inhibitors (e.g., bafilomycin A1)

  • Measure p62/SQSTM1 degradation as an indicator of autophagic activity

• Signaling pathway analysis:

  • Evaluate AMPK-ULK1 pathway activation through phospho-specific antibodies

  • Assess mTOR signaling components (phospho-mTOR, p70S6K, 4E-BP1)

  • Use pathway inhibitors and activators as experimental controls

• Functional consequences:

  • Determine the impact of autophagy inhibition on BP9's immunomodulatory effects

  • Analyze B cell development, survival, and function in the context of BP9-induced autophagy

• Mechanistic studies:

  • Investigate direct binding partners of BP9 using pull-down assays or surface plasmon resonance

  • Perform structure-activity relationship studies with BP9 variants

These approaches will help elucidate the mechanistic link between BP9 treatment, autophagy induction, and subsequent immunomodulatory effects .

What are the current limitations in BP9 research and how might they be addressed?

Current BP9 research faces several challenges that researchers should address:

• Receptor identification:
  The specific receptor(s) through which BP9 exerts its effects remain unidentified. Future studies should employ:

  • Cross-linking studies with labeled BP9

  • Affinity chromatography followed by mass spectrometry

  • CRISPR-Cas9 screening to identify essential genes for BP9 responsiveness

• Structure-function relationships:
  Understanding which amino acids within the BP9 sequence are critical for its activity would provide valuable insights. Approaches include:

  • Alanine scanning mutagenesis

  • Structure determination (NMR or X-ray crystallography)

  • Peptide truncation studies

• Translational applications:
  Moving beyond proof-of-concept studies to develop BP9 as a practical adjuvant requires:

  • Optimization of formulation and delivery methods

  • Comprehensive safety and toxicity studies

  • Comparison with established adjuvants

Addressing these limitations will advance our understanding of BP9's mechanism of action and potential applications in vaccine development .

How might BP9 research intersect with other emerging immunological approaches?

BP9 research can be integrated with several cutting-edge immunological approaches:

• Single-cell technologies:
  Single-cell RNA-seq and CyTOF could reveal heterogeneity in B cell responses to BP9, identifying responsive subpopulations and characterizing their developmental trajectories.

• Systems immunology:
  Multi-omics approaches combining transcriptomics, proteomics, and metabolomics could provide a comprehensive view of BP9's effects across different biological scales.

• Structural biology and computational modeling:
  Molecular dynamics simulations and structure-based drug design could help optimize BP9 derivatives with enhanced stability or efficacy.

• Synthetic biology:
  Engineering cellular circuits responsive to BP9 could create novel therapeutic systems with controlled immunomodulatory properties.

• AI-driven antibody design:
  Integrating knowledge of BP9's effects with emerging AI platforms like RFdiffusion could enable the design of antibodies with enhanced properties when stimulated by BP9 .

These interdisciplinary approaches could significantly accelerate our understanding of BP9's mechanism and expand its potential applications.